IRIS
TACCONELLI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.065
NA - Nord America 3.018
AS - Asia 1.410
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 4
SA - Sud America 4
Totale 7.515
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.013
CN - Cina 613
UA - Ucraina 526
IE - Irlanda 507
IT - Italia 427
GB - Regno Unito 373
SE - Svezia 352
TR - Turchia 341
SG - Singapore 336
FR - Francia 315
DE - Germania 188
FI - Finlandia 118
PL - Polonia 100
RU - Federazione Russa 88
IN - India 78
CZ - Repubblica Ceca 27
BE - Belgio 23
JP - Giappone 9
VN - Vietnam 9
IR - Iran 7
AE - Emirati Arabi Uniti 6
NL - Olanda 6
EU - Europa 5
ZA - Sudafrica 5
BR - Brasile 4
BY - Bielorussia 4
AT - Austria 3
AU - Australia 3
GR - Grecia 3
IL - Israele 3
CA - Canada 2
HK - Hong Kong 2
MX - Messico 2
PH - Filippine 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
CG - Congo 1
CH - Svizzera 1
EE - Estonia 1
EG - Egitto 1
ES - Italia 1
GT - Guatemala 1
ID - Indonesia 1
KZ - Kazakistan 1
MA - Marocco 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
Totale 7.515
Salva come PNG Salva come JPEG
Città #
Chandler 662
Jacksonville 583
Dublin 498
Southend 312
Singapore 276
Princeton 220
Dearborn 182
Izmir 170
Nanjing 155
Ashburn 109
Beijing 105
Wilmington 101
Kraków 98
Cambridge 95
Chieti 83
Altamura 79
Ann Arbor 67
Nanchang 63
Boardman 53
Santa Clara 51
Shenyang 42
Woodbridge 38
Munich 34
Hebei 29
Changsha 27
Grevenbroich 27
Los Angeles 25
Helsinki 23
Jiaxing 23
Brno 22
Tianjin 22
Kocaeli 21
Washington 21
Brussels 20
Kunming 20
New York 18
Orange 17
Seattle 17
Hangzhou 16
Norwalk 15
Spoltore 14
Shanghai 13
Düsseldorf 11
Hefei 11
Jinan 11
Leawood 11
Lanzhou 10
Dong Ket 9
Guangzhou 9
Rome 9
Augusta 8
Houston 8
Montesilvano 8
Romola 8
Menlo Park 7
Pescara 7
Fuzhou 6
L’Aquila 6
Ningbo 6
San Mateo 6
Simi Valley 6
Auburn Hills 5
Cape Town 5
Dubai 5
Olomouc 5
Perm 5
Taizhou 5
Tavagnacco 5
Changchun 4
Mogilev 4
Mumbai 4
São Paulo 4
Tappahannock 4
Zhengzhou 4
Ardabil 3
Bari 3
Glasgow 3
Lappeenranta 3
Moscow 3
Sagamino 3
San Giovanni Teatino 3
Tagara 3
Walnut 3
Amsterdam 2
Ankara 2
Antalya 2
Anzano Del Parco 2
Ashford 2
Avezzano 2
Bernareggio 2
Bologna 2
Bruges 2
Caravaggio 2
Clearwater 2
Ferrara 2
Fiano Romano 2
Florence 2
Gifu 2
Grafing 2
Hanover 2
Totale 4.743
Salva come PNG Salva come JPEG
Nome #
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 190
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 121
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 109
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 107
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 107
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 100
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 99
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 99
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 98
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 93
Oxidative stress and platelet activation in essential hyperytension 92
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 92
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 91
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 91
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 90
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 90
New insights into COX-2 biology and inhibition. 88
Antithrombotic Agents and Cancer 88
Platelet activation in patients with colorectal cancer. 87
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 87
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 86
Pharmacodynamic of cyclooxygenase inhibitors in humans. 84
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 83
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 83
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 82
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 82
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 82
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 81
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 81
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 80
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 80
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 79
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 78
Mechanistic and pharmacological issues of aspirin as an anticancer agent 78
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 77
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 76
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 75
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 75
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 75
Effects of Acetaminophen on Constitutive and Inducible Prostanoid Biosynthesis in Human Blood Cells in vitro 74
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 74
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 74
Clinical pharmacology of selective COX-2 inhibitors. 74
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 74
EFFECTS OF CELECOXIB ON SYSTEMIC MARKERS OF PROSTANOID GENERATION AND INFLAMMATION AND ANGIOGENESIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS: A BIOMARKER CLINICAL STUDY. 72
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 72
P2Y12 Receptors in Tumorigenesis and Metastasis 72
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 70
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. 70
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 70
Gut microbiota, host gene expression, and aging. 70
“ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS" 69
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 69
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 69
“DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOSSIGENASI” 68
Clinical pharmacology of novel selective COX-2 inhibitors. 68
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 68
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 68
NSAIDs and cardiovascular disease. 68
Risk management profile of etoricoxib: An example of personalized medicine 68
Human pharmacology of naproxen sodium. 68
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 67
Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina 67
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 65
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 65
Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. 63
Functionalized diarylisoxazoles inhibitors of ciclooxygenase 63
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 62
CLINICAL PHARMACOLOGY OF PLATELET COX INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 61
ISOPROSTANES: ARE THEY MORE THAN PHYSIOPATHOLOGICAL BIOMARKERS OF LIPID PEROXIDATION? RESPONSE. 61
Clinical pharmacology of etoricoxib. 61
Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. 61
Reduced thromboxane biosynthesis in carriers of Toll-like receptor 4 polymorphisms in vivo 61
Determinants of platelet activation in human essential hypertension. 61
Managing the adverse effects of nonsteroidal anti-inflammatory drugs. 61
INCREASED OXIDATIVE STRESS IN RENOVASCULAR HYPERTENSION. 60
INHIBITION OF INDUCILE CYCLOOXYGENASE ACTIVITY BY GLUCOCORTICOIDS IN MAN. 59
Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. 58
Enhanced thromboxane biosynthesis in patients with colorectal and lung cancer 58
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS. 57
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCILE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS IN VITRO. 57
Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis 57
DIFFERENTIAL ASSOCIATION BETWEEN HUMAN PROSTACYCLIN RECEPTOR POLYMORPHISMS AND THE DEVELOPMENT OF VENOUS THROMBOSIS AND INTIMAL HYPERPLASIA: A CLINICAL BIOMARKER STUDY. 56
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 56
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 55
Mode of action of aspirin as a chemopreventive agent. 55
Parmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 54
Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A2 is unrestrained 54
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES. 53
OXIDANT STRESS AND PLATELET ACTIVATION IN ESSENTIAL HYPERTENSION. 53
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 53
Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. 53
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 53
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES 52
Platelets induce free and phospholipid-esterified 12-hydroxyeicosatetraenoic acid generation in colon cancer cells by delivering 12-lipoxygenase 52
Isoprostanes and other markers of peroxidation in atherosclerosis. 51
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia 50
Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System 50
Oxidative Damage, Platelet Activation, and Inflammation to Predict Mobility Disability and Mortality in Older Persons: Results From the Health Aging and Body Composition Study. 49
HETEROGENEITY IN THE SUPPRESSION OF PLATELET CYCLOOXYGENASE-1 ACTIVITY BY ASPIRIN IN CARDIOVASCULAR DESEASE. 48
Totale 7.317
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.633
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.633
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020776 0 0 0 0 89 114 188 148 30 76 122 9
2020/2021752 110 2 107 8 69 129 29 23 51 124 47 53
2021/2022489 7 11 14 132 16 5 16 43 45 14 56 130
2022/20231.732 124 220 78 223 165 347 100 136 230 21 30 58
2023/2024808 52 31 69 25 63 225 183 23 5 19 9 104
2024/2025685 123 272 198 43 49 0 0 0 0 0 0 0
Totale 7.935